Install
Cell & Gene Therapies
CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Cell & Gene Therapies
Could Gene Therapy Transform Neurological Disease Treatment? A $7 Billion Market Opportunity by 2030
2+ hour, 39+ min ago (213+ words) Driven by rapid advancements in precision gene-editing technologies like CRISPR, rising global awareness of rare genetic disorders, and significant investments in specialized healthcare infrastructure, the global Gene Therapy On Neurological Diseases Market is projected to surpass $7 billion by 2030. The sector…...
CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety
1+ hour, 6+ min ago (331+ words) CRISPR Medicine News CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety Many cell and gene therapy (CGT) developers use gene editing techniques to generate the therapy or produce the desired therapeutic outcome. However, standard quality control and analytical methods…...
CRISPR Milestone and Gene Therapy Redefine the Curative Landscape of Beta-Thalassemia
2+ hour, 29+ min ago (754+ words) A new review charts how stem cell transplantation, lentiviral gene therapy, and CRISPR-based editing such as Casgevy are turning beta-thalassemia from a lifelong transfusion-dependent illness into a potentially curable disease, while cost and access hurdles remain steep....
ASO gene silencing reaches further, lasts longer
13+ hour, 6+ min ago (720+ words) Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon? Since the HD gene was identified, nearly 20 years ago, scientists have been trying to understand what it does, how it causes the symptoms…...
Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma
18+ hour, 58+ min ago (359+ words) OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats. [In vivo CAR T-cell therapy] avoids all the logistics of the autologous and also allogeneic CAR T[-cell therapies] in terms…...
Liver Injury After CAR T-Cell Therapy May Be Driven by Cytokine Storm, Landmark Analysis Finds
1+ day, 3+ hour ago (649+ words) A pharmacovigilance analysis of nearly five million adverse-event reports finds that liver injury after CAR T-cell therapy is predominantly early and linked to cytokine release syndrome, though a persistent CRS-independent signal with idecabtagene vicleucel warrants prospective study....
Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 Trial
1+ day, 12+ hour ago (559+ words) STAT reported on Oct. 7 that the company is shutting down. Chief executive Rachel Haurwitz told STAT that Caribou had worked out a phase 3 design with the FDA, but raising money to pay for the study proved too difficult. For patients…...
CAR-T vs Stem Cell Transplantation: Where Are Practice and Science Heading in 2026?
1+ day, 14+ hour ago (1129+ words) Growing evidence for CAR-T and its expanding use across hematologic malignancies are fueling comparisons with stem cell transplantation. Their relative roles differ sharply by disease and clinical setting. The latest EBMT activity survey, covering 2024, recorded 47,204 HCT procedures. Allo-HCT rose 2.6% from…...
Nepal-made CAR-T cell therapy used to treat blood cancer patient
1+ day, 16+ hour ago (52+ words) Hamro Patro myrepublica.nagariknetwork.com · Sat Oct 10 08:45:00 GMT 2026 KATHMANDU, Oct 10: A 17-year-old blood cancer patient has been treated with CAR-T cell therapy produced in Nepal for the first time, marking a milestone in the country’s cancer treatment sector....
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
1+ day, 16+ hour ago (886+ words) CancerNetwork CancerNetwork® spoke with Ralph V Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown University Hospital, and medical director of the International Oncology Network Clinical Research Program, about how he…...